Patents Examined by Melissa Schmidt
-
Patent number: 6252058Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: GrantFiled: November 5, 1998Date of Patent: June 26, 2001Inventor: Timothy C. Thompson
-
Patent number: 6200753Abstract: A method for increasing the specificity of hybridization between a nucleic acid probe and a nucleic acid sequence to be detected, by addition of blocker molecules, which are complementary to the probe, raise of temperature in order to melt non-perfectly matched hybrids of probe and detected nucleic acid sequences, and lowering of the temperature again.Type: GrantFiled: February 27, 1998Date of Patent: March 13, 2001Assignee: Intelligene Ltd.Inventor: Asher Nathan
-
Patent number: 6168950Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.Type: GrantFiled: July 23, 1999Date of Patent: January 2, 2001Assignee: Isis Pharmaceuticals, Inc.Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Lex M. Cowsert
-
Patent number: 6159714Abstract: Nucleic acid able to cause specific cleavage of a bond between two ribonucleotides in an RNA-containing molecule. The RNA-containing molecule has the structure:5'-XnUHZCUGANGAGYm-3'wherein each X and Y is independently any nucleotide base; n and m are independently between 5 and 40; H is U, A or C; Z is a hairpin loop, having between 6 and 60 bases, and each U, C, G and A is a uracil, cytosine, guanosine, or adenosine-containing ribonucleotide, respectively, and N is any ribonucleotide. The nucleic acid has the structure:3'-X'nM.sub.o Y'm-5'wherein each X' and Y' are complementary nucleotide bases to each corresponding X and Y, and M.sub.o is a series of nucleotide bases active to cause the cleavage, and wherein M.sub.o contains no ribonucleotides.Type: GrantFiled: March 12, 1998Date of Patent: December 12, 2000Assignee: Ribozyme Pharmacueticals, Inc.Inventors: Nassim Usman, Robert J. Cedergren, Pascal Chartrand, Stephen C. Harvey
-
Patent number: 6136536Abstract: Disclosed are methods, DNA sequences, vectors and cell lines useful for the rapid generation of stable mammalian cell lines expressing high levels of recombinant proteins.Type: GrantFiled: October 20, 1998Date of Patent: October 24, 2000Assignee: Genetics Institute, Inc.Inventors: Kathleen Tomkinson, Monique Davies, John McCoy
-
Patent number: 6136603Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor.alpha. are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.Type: GrantFiled: March 26, 1999Date of Patent: October 24, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Nicholas M. Dean, James G. Karras, Robert McKay
-
Patent number: 6130088Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Telomeric Repeat Binding Factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Telomeric Repeat Binding Factor 1. Methods of using these compounds for modulation of Telomeric Repeat Binding Factor 1 expression and for treatment of diseases associated with expression of Telomeric Repeat Binding Factor 1 are provided.Type: GrantFiled: July 21, 1999Date of Patent: October 10, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Brett P. Monia, Lex M. Cowsert
-
Patent number: 6121047Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-1. Methods of using these compounds for modulation of SHP-1 expression and for treatment of diseases associated with expression of SHP-1 are provided.Type: GrantFiled: July 21, 1999Date of Patent: September 19, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: C. Frank Bennett, Lex M. Cowsert
-
Patent number: 6120998Abstract: Endo-xyloglucan transferases responsible for growth of plant cell wall, genes coding for the enzymes, a method of transferring xyloglucan molecules by using the enzyme, and methods of using the gene are described.Type: GrantFiled: March 31, 1998Date of Patent: September 19, 2000Assignee: Takara Shuzo Co., Ltd.Inventors: Kazuhiko Nishitani, Kazuhide Okazawa, Kiyozo Asada, Ikunoshin Kato
-
Patent number: 6114152Abstract: Nucleic acids are made by adding a known nucleotide sequence to the 3' end of a first RNA having a known sequence at the 5' end to form a second RNA and reverse transcribing the second RNA to form a cDNA. In one embodiment, the first RNA is an amplified mRNA, the known sequence at the 5' end comprises a poly(T) sequence, the adding step comprises using a polyadenyltransferase to add a poly(A) sequence to the 3' end, the reverse transcribing step is initiated at a duplex region comprising the poly(T) sequence hybridized to the poly(A) sequence, the cDNA is converted to double-stranded cDNA by a polymerase initiating from a noncovalently joined duplex region, and the double-stranded cDNA is transcribed to form one or more third RNAs.Type: GrantFiled: March 27, 1998Date of Patent: September 5, 2000Assignee: The Regents of the University of CaliforniaInventors: Tito Serafini, Percy Luu, John Ngai, David Lin
-
Patent number: 6107091Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-16. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-16. Methods of using these compounds for modulation of G-alpha-16 expression and for treatment of diseases associated with expression of G-alpha-16 are provided.Type: GrantFiled: December 3, 1998Date of Patent: August 22, 2000Assignee: Isis Pharmaceuticals Inc.Inventor: Lex M. Cowsert
-
Patent number: 6087168Abstract: The present invention is directed to method of converting, or transdifferentiating the epidermal cells into viable neurons useful in both cell therapy and gene therapy treatment methodologies. The method of transdifferentiating epidermal cells into neuronal cells comprises the following steps: obtaining skin cells from a patient; dedifferentiating these cells with an appropriate medium, neurotrophin or cytokine; transfecting the skin cells with one or more expression vector(s) encoding at least one neurogenic transcription factor or active fragments thereof; expressing at least one of the neurogenic transcription factors; growing the transfected cells in an appropriate medium; and adding to the medium one or more antisense oligonucleotide(s) corresponding to at least one negative regulator of neuronal differentiation, whereby the epidermal cells are transdifferentiated into neuronal cells.Type: GrantFiled: January 20, 1999Date of Patent: July 11, 2000Assignee: Cedars Sinai Medical CenterInventors: Michel F. Levesque, Toomas Neuman
-
Patent number: 6087484Abstract: Methods are disclosed for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme and a 2'-O-substituted facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme and an effective amount of a 2'-O-methyl substituted facilitator oligonucleotide. The use of a facilitator, particularly a 2'-O-substituted facilitator, and more especially a 2'-O-methyl substituted facilitator, greatly enhances ribozyme catalytic activity, frequently making an otherwise inactive ribozyme active.Type: GrantFiled: March 18, 1997Date of Patent: July 11, 2000Assignee: University of Massachusetts WorcesterInventor: John Goodchild
-
Patent number: 6080580Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-.alpha. (TNF-.alpha.). Antisense oligonucleotides targeted to nucleic acids encoding TNF-.alpha. are preferred. Methods of using these oligonucleotides for inhibition of TNF-.alpha. expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-.alpha. are provided.Type: GrantFiled: October 5, 1998Date of Patent: June 27, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan, Jr.
-
Patent number: 6069008Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p65 subunit. Methods of using these compounds for modulation of NF-kappa-B p65 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p65 subunit are provided.Type: GrantFiled: November 25, 1998Date of Patent: May 30, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
-
Patent number: 6066500Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Beta catenin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Beta catenin. Methods of using these compounds for modulation of Beta catenin expression and for treatment of diseases associated with expression of Beta catenin are provided.Type: GrantFiled: June 25, 1999Date of Patent: May 23, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: C. Frank Bennett, Lex M. Cowsert
-
Patent number: 6046006Abstract: A method and kit for detecting fungal cells in clinical material utilizing nucleic acid hybridization probes identified as SEQ. ID NO. 9-12.Type: GrantFiled: April 26, 1999Date of Patent: April 4, 2000Assignees: Eberhard-Karls-Universitat, Tubingen UniversitatsklinikumInventors: Hermann Einsele, Jurgen Loffler
-
Patent number: 6046049Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 delta. Methods of using these compounds for modulation of PI3 kinase p110 delta expression and for treatment of diseases associated with expression of PI3 kinase p110 delta are provided.Type: GrantFiled: July 19, 1999Date of Patent: April 4, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Brett P. Monia, Lex M. Cowsert
-
Patent number: 6043091Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of liver glycogen phosphorylase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding liver glycogen phosphorylase. Methods of using these compounds for modulation of liver glycogen phosphorylase expression and for treatment of diseases associated with expression of liver glycogen phosphorylase are provided.Type: GrantFiled: July 19, 1999Date of Patent: March 28, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Brett P. Monia, Lex M. Cowsert
-
Patent number: 6040179Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i2. Methods of using these compounds for modulation of G-alpha-i2 expression and for treatment of diseases associated with expression of G-alpha-i2 are provided.Type: GrantFiled: June 25, 1999Date of Patent: March 21, 2000Assignee: Isis Pharmaceuticals Inc.Inventor: Lex M. Cowsert